Month: March 2012

(Reuters) – the food and drug administration of United States ( FDA) responded to the growing concern about the safety of metal hip prosthesis saying that undergo the devices to a review of two days of length by experts, which could lead to fix more rigorous standards. The FDA announced that a panel will be meeting on 27 and 28 June integrated Advisor by scientists, researchers, patients and medical assisting regulators to decide if they are imposed new standards of assessment and review requirements to must be met before that one of these prostheses may sold in United States. “we are consulting with experts, doctors and scientists “ external to discuss the recent information on these devices, so that the Agency can continue to “ reliable recommendations in terms of security”, indicated in a release Dr. William Maisel, Deputy Director of science of the Center for devices and health radiation of the FDA. The actions of manufacturers of Orthopedic devices -including Stryker Corp, Zimmer Holdings Inc and Johnson & Johnson – fell after the announcement, made on Thursday. Hip replacement surgery is a common procedure and expensive that it seeks to provide greater mobility and pain relief to persons with problems joints, including arthritis. Each year, United States, occur in about 270,000 hip replacements, which represents almost 40 by cent of all replacements joints, according to British Medical Journal....

new YORK (Reuters Health) – research conducted in Australia revealed who spent much time sitting front desk or television were more likely to die for any cause for three years to persons who a few hours a day were sedentary. This suggests that replace some of that time in a wheelchair with physical activity gentle, such as walking and doing the tasks of the home, would have important benefits in the long run. “when you tell people how much physical activity “ should do too must talk about how reducing the “ amount of hours per day that involves sitting”, said Hidde van der Ploeg, of the University of Sydney. Among more than 200,000 older than 45 years, the team of Van der Ploeg noted that those who remained seated at least 11 hours a day were 40 percent more likely to die during the study than those who did less than four hours a day. Even so, the complainant clarified that does not prove that be of hours seated shorten life. But the results are consistent with recent studies that they suggested that many hours in a Chair health consequences, said Mark Tremblay, expert obesity and children Hospital, Ontario physical activity East, Ottawa. “sit or lay, especially in front of a screen, “” is bad for health regardless of age”, said Tremblay, to did not participate in the...

Zurich (Reuters) – the laboratory Roche reported that patients with aggressive a type of breast cancer lived by more time without the disease worsening after receiving his experimental drug “loaded with antibodies”, compared with who received a mixture of their drug Xeloda next to Tykerb by GlaxoSmithKline. The positive results of the first phase III trial on new medicine-nicknamed T DM1 – pave the way towards the requested approval this year to European authorities and Americans, which improves the odds of an asset pending approval is key to the Swiss firm. Analyst WestLB Oliver Kaemmerer, which sees peaks of sales potential for T-DM1 around 1 billion of Swiss francs ($ 1.1 billion), said that the news was clearly positive, but that remains to see what was the general magnitude of benefit in the study. In a brief statement Friday Roche revealed only to the patients treated with T-DM1 lived “time “” significantly more” unless his illness progress. Roche has developed T-DM1 as successor of their leader sales Herceptin, which is expected this year to generate sales of around $ 6 billion. A clear advantage of T-DM1 on conventional treatment Herceptin plus chemotherapy is the fact that causes less as hair loss and low count side effects of white blood cells. T-DM1 combining trastuzumab, an antibody and the ingredient Active of Herceptin, with agent DM1 – a derivative of a...